Ocumetics Technology Corp. (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) reported highly encouraging six-month postoperative results from the first group of patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The outcomes exceed expectations, with all patients experiencing continuing vision improvements and a strong safety profile.
Patients entered the study with very poor vision, including one individual considered legally blind. At six months post-surgery, patients continue to demonstrate improved vision and stable visual acuity. Anecdotally, all patients reported life-changing results, such as reading, driving, and living independently again. The company is leveraging surgeon feedback and patient experience into ongoing product enhancements, with updated lens refinements currently in manufacturing and testing to support the planned initiation of Group Two surgeries.
“After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “Patients who entered this study with severely impaired vision are now reading, driving, and living independently again. We’re developing a technology that dramatically improves people’s quality of life and we couldn’t be happier.”
The results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens, which is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses. The company will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the results. Registration is available at www.ocumetics.com/webinar.
“The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program,” added Burns. “We are not only validating our technology, we are demonstrating its real-world impact. Our focus now is to build on this success, further optimize performance, and bring this life changing solution to more patients.”
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is in the first-in-human early feasibility study phase of a dynamic intraocular lens that fits within the natural lens compartment of the eye. For further information, contact Dave Burwell, Director, Investor Relations, at dave.burwell@ocumetics.com or (403) 410-7907. The original release is available at www.newmediawire.com.
